Latest Developments and Insights on ADCs for Lung Cancer

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
Transforming Precision Lung Cancer Care: Expert Guidance on HER2-, HER3-, TROP2-, and B7-H3–Targeted ADCs

Content Format:

Video

Credit Type:

AMA | EBAC®

Credits:

1.50
Transforming Precision Lung Cancer Care: Expert Guidance on HER2-, HER3-, TROP2-, and B7-H3-Targeted ADCs

Content Format:

Credits Only

Credit Type:

AMA | EBAC®

Credits:

1.50
Expanding the Applicability Beyond HER2m and EGFRm: TROP-2–Targeted ADCs in NSCLC and ADCs in Patients with SCLC

Content Format:

Slideset

Credit Type:

--

Credits:

--
Mapping TROP-2–Targeted ADCs Into the NSCLC Treatment Landscape

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
TROP-2–Targeted ADCs for NSCLC: ​Integrating a New Therapeutic Option

Content Format:

Video

Credit Type:

AMA | EBAC®

Credits:

1.25
Antibody–Drug Conjugates and the Role of TROP-2 in NSCLC

Content Format:

Slideset

Credit Type:

--

Credits:

--
TROP-2–Targeted ADCs for NSCLC: Integrating a New Therapeutic Option

Content Format:

Credits Only

Credit Type:

AMA | EBAC®

Credits:

1.50
The Potential of Antibody‒Drug Conjugates Targeting CEACAM5 in NSCLC

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
Research Focus: Targeting CEACAM5 With Novel Antibody‒Drug Conjugates in Nonsquamous Non-Small-Cell Lung Cancer

Content Format:

Text Module

Credit Type:

AMA

Credits:

0.50
Research Focus: Targeting CEACAM5 With Novel Antibody-Drug Conjugates in Nonsquamous Non-Small-Cell-Lung Cancer

Content Format:

Slideset

Credit Type:

--

Credits:

--
Key Studies in Breast, Gynecologic, Renal Cell, Urothelial, Lung, Hepatobiliary, and Skin Cancers: CCO Independent Conference Highlights of the 2022 ESMO Congress

Content Format:

Text Module

Credit Type:

AMA

Credits:

1.25
An Expert’s Guide to ESMO 2022: A Preview of the Top Abstracts

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
Current Status of EGFR Tyrosine Kinase Inhibitor Combination Therapy in the Treatment of Newly Diagnosed EGFR-Mutated Advanced NSCLC

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
First-line Osimertinib for EGFR-Mutated Advanced NSCLC: Barriers to Access and Future Directions

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
Congress to Clinic: Post-ELCC Updates on Antibody–Drug Conjugates in NSCLC

Content Format:

Podcast Episodes

Credit Type:

--

Credits:

--
Congress to Clinic: Post-ELCC Updates on Antibody–Drug Conjugates in NSCLC

Content Format:

Multimedia

Credit Type:

AMA

Credits:

1.00
Express PointsCongress to Clinic: Post-ELCC Updates on Antibody–Drug Conjugates in NSCLC

Content Format:

Slideset Download

Credit Type:

--

Credits:

--
Activity of ADCs in Clinical Trials for Lung Cancer: Anti–TROP-2/CEACAM/c-Met ADCs

Content Format:

Slideset Download

Credit Type:

--

Credits:

--